Charles River (NYSE: CRL) interim CFO reports stock award and share move
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Charles River Laboratories International, Inc. executive Michael Gunnar Knell, CSVP, CAO and Interim CFO, reported equity-related transactions in company common stock. On January 30, 2026, he acquired 1,668 shares at $0 per share, reflecting performance share units earned from awards granted on May 26, 2023.
On the same date, Knell disposed of 526 shares of common stock at $211.68 per share. After these transactions, he directly held 14,602 shares of Charles River Laboratories common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Knell Michael Gunnar
Role
CSVP, CAO, Interim CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 1,668 | $0.00 | -- |
| Tax Withholding | Common Stock | 526 | $211.68 | $111K |
Holdings After Transaction:
Common Stock — 15,128 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What insider transactions did CRL executive Michael Gunnar Knell report?
Michael Gunnar Knell reported acquiring 1,668 Charles River Laboratories common shares at $0 and disposing of 526 shares at $211.68 on January 30, 2026. Following these transactions, he directly held 14,602 CRL common shares.
What is the role of Michael Gunnar Knell at Charles River Laboratories (CRL)?
Michael Gunnar Knell serves as CSVP, Chief Accounting Officer, and Interim Chief Financial Officer of Charles River Laboratories International, Inc. His Form 4 filing reflects changes in his directly held CRL common stock position on January 30, 2026.
What do the transaction codes A and F indicate in Knell’s CRL Form 4?
The Form 4 shows code A for the acquisition of 1,668 CRL common shares at $0 and code F for the disposition of 526 shares at $211.68. These codes categorize the nature of each reported equity transaction.